Product Description
Beroctocog alfa is a second generation recombinant factor VIII manufactured by removing the B-domain from factor VIII. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479860/)
Mechanisms of Action: FVIII Analogue
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Philippines | Vietnam
Approved Indications: None
Company: Green Cross
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hemophilia A
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2012-001445-40 |
GreenGene F_P3 | P3 |
Terminated |
Hemophilia A |
2015-04-30 |
2022-03-13 |
Treatments |
|
2013-004383-62 |
2013-004383-62 | P3 |
Terminated |
Hemophilia A |
2015-01-20 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/12/2021 |
News Article |
GC Pharma Announces GreenGene F Approval in China for the Treatment of Haemophilia A |